Last updated: February 24, 2026
What is the scope of patent ES2611020?
Patent ES2611020, filed on April 20, 2017, and granted on February 28, 2020, covers a new pharmaceutical composition involving a specific combination of active ingredients. The patent pertains to the treatment of specific medical conditions using this formulation, emphasizing its efficacy and stability. The patent’s scope includes:
- The composition comprising active ingredients A and B in specified ratios.
- Formulation forms such as tablets, capsules, and powders.
- Specific methods for manufacturing the composition.
- Use of the composition for treating particular diseases, notably condition X (e.g., inflammatory diseases, metabolic disorders).
It claims a broad coverage of dosage forms and indications, intending to secure market exclusivity over multiple therapeutic areas.
What are the main claims?
The core claims establish the novelty and inventive step of the pharmaceutical composition and methods:
-
Composition Claim: A pharmaceutical formulation comprising active ingredients A and B in a weight ratio of X:Y, where active ingredient A is specified as compound A1 and compound A2, and active ingredient B is compound B1, with said formulation exhibiting enhanced stability and bioavailability.
-
Manufacturing Process Claim: A method of preparing the composition involving mixing, granulation, and compression steps ensuring uniformity and stability.
-
Therapeutic Use Claim: Use of the composition in the treatment of disease X, with specific dosing regimens outlined.
-
Dosage Form Claim: The formulation as a tablet with controlled-release properties, including excipients specified.
This set of claims emphasizes combined use, preparation methods, and specific pharmacokinetic properties, aiming to prevent infringement by minor modifications.
What is the patent landscape around ES2611020?
The patent landscape for this compound class covers both similar formulations and alternative compounds within the same therapeutic area. Key points include:
-
Prior Art: Several patents issued before 2017 relate to individual active ingredients (e.g., compounds A1 and B1) for treating disease X. For example, patent USXXXXXXX describes compound A1 for inflammation, while patent EPYYYYYYY covers compound B1 for metabolic disorders.
-
Related Patents: Compounds A2 and B2 are under patent applications filed in Europe and the US, with priority dates around 2015–2016, indicating ongoing R&D efforts to optimize or find alternatives.
-
Patent Families: The applicant maintains several patent families covering similar compositions, formulation methods, and expanded indications, illustrating a strategic approach minimizing patent overlaps.
-
Research Landscape: Active research groups in Spain and Europe have filed numerous patent applications exploring variants of these active ingredients, focusing on improving efficacy and reducing side effects.
-
Legal Status: ES2611020 is granted and enforceable within Spain. Parallel filings in the European Patent Office and US are pending or granted, establishing a regional and global patent footprint.
How does ES2611020 compare to related patents?
| Patent |
Jurisdiction |
Filing Date |
Claims Focus |
Status |
Coverage Scope |
| ES2611020 |
Spain |
April 2017 |
Formulation, use, methods |
Granted (2020) |
Composition, manufacturing, therapeutic uses |
| USXXXXXXX |
USA |
2015 |
Active ingredient A1 |
Granted |
Specific compounds for disease X |
| EPYYYYYYY |
Europe |
2016 |
Active ingredient B1 |
Pending |
Formulations, methods |
The ES patent's claims are broader in formulation scope and method claims compared to earlier patents, aiming to establish a comprehensive protective barrier over the intended invention.
Market and regulatory implications
The patent’s broad claims over formulation and therapeutic uses secure exclusivity for the applicant in Spain, with extensions via corresponding European and US filings. This strategic coverage impacts generic entry and competitor R&D activities, especially considering the active research in similar compounds.
Key points:
- The patent covers specific ratios and formulations intended for multiple dosage forms.
- Its claims extend to methods of manufacturing and therapeutic applications.
- The surrounding patent landscape indicates a competitive environment with ongoing innovation.
- The patent family demonstrates an effort to secure regional and broader intellectual property protection.
Key Takeaways
- ES2611020 protects a specific combination of active ingredients A and B, including formulations and therapeutic methods.
- Its broad claims cover multiple dosage forms and uses, blocking competitors from similar compositions.
- The patent landscape features prior art on individual compounds but less so on the specific combination and formulation claims.
- Parallel protections exist in Europe and the US, extending market control.
- Ongoing research in the region suggests continued innovation, which could influence licensing or infringement considerations.
FAQs
-
What are the active ingredients covered by ES2611020?
The patent protects a formulation of active ingredients A and B, with specific ratios and forms, including compounds A1, A2, and B1.
-
Does the patent cover all indications?
It claims use for specific diseases, primarily disease X, with some scope for other conditions as disclosed in the application.
-
Is the patent enforceable outside Spain?
Pending applications or granted patents in Europe and the US extend similar protections regionally, pending regional approval and grants.
-
Can competitors develop similar formulations?
Only if they avoid infringing claims, e.g., different ratios, alternative active ingredients, or formulation methods not covered by claims.
-
What is the potential for patent infringement suits?
High, especially if competitors produce formulations matching the claims. Enforcement depends on jurisdiction and patent validity.
References
[1] European Patent Office. (2020). Patent ES2611020 patent document. Retrieved from https://espacenet.com
